Continuing erythropoietin during peripheral blood stem cell collection in myeloma: can it reduce toxicity of autologous transplants?
Labonté
Laura
L
Iqbal
Tariq
T
McDiarmid
Sheryl
S
Bence-Bruckler
Isabelle
I
Huebsch
Lothar
L
Allan
David
D
D000328:Adult; D000368:Aged; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006454:Hemoglobins / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D011994:Recombinant Proteins; D014182:Transplantation, Autologous / Q000009:adverse effects / Q000379:methods
D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin